Chen Jiaqi, Bai Gang, Yang Yang, Geng Peng, Cao Yu, Zhu Yuanyuan
Department of Microbiology, College of Life Sciences, Nankai University, Tianjin 30071, China.
Peptides. 2007 Apr;28(4):928-34. doi: 10.1016/j.peptides.2006.12.012. Epub 2006 Dec 27.
Glucagon-like peptide-1 (GLP-1) stimulates insulin and inhibits glucagon secretion and therefore could potentially be used to treat diabetes type II. However, its therapeutic use is limited by its short half-life in vivo, due mainly to enzymatic degradation by dipeptidyl peptidase IV (DPP-IV). Developing GLP-1 analogs with greater bioactivity is therefore an important step toward using them therapeutically. Accordingly, we aimed to identify GLP-1 mimetic peptides by creating a high-throughput screening (HTS) assay of a phage displayed (PhD) peptide library. This assay was functionally based using the GLP-1 receptor (GLP-1R) gene. Rat GLP-1R cDNA was transfected into CHO/enhanced green fluorescent protein (EGFP) cells by lipofection. The resulting stable, recombinant cell line functionally expressed the GLP-1R and a cAMP-responsive EGFP reporter gene, to monitor receptor activation, and was used to screen a PhD dodecapeptide library. After four rounds of selection, 10 positive clones were selected based on functional evaluation and sequenced. Three sequences were obtained, corresponding to three different domains of GLP-1 (Group 1: 22-34; Group 2: 18-29; and Group 3: 6-17). The Group 3 peptide had the highest bioactivity, was synthesized, and designated KS-12. Importantly, KS-12 activated GLP-1R in vitro and reduced blood glucose levels in a dose-dependent manner when administered to Chinese Kunming mice. Although KS-12 was not as effective as GLP-1, it was significantly resistant to DPP-IV both in vitro and in vivo. Thus, this study provides a novel way to screen DPP-IV resistant agonist peptides of GLP-1 from a PhD peptide library using the functional reporter gene HTS assay.
胰高血糖素样肽-1(GLP-1)可刺激胰岛素分泌并抑制胰高血糖素分泌,因此有可能用于治疗2型糖尿病。然而,其在体内的半衰期较短,主要由于二肽基肽酶IV(DPP-IV)的酶促降解作用,限制了它的治疗用途。因此,开发具有更高生物活性的GLP-1类似物是将其用于治疗的重要一步。相应地,我们旨在通过对噬菌体展示(PhD)肽库进行高通量筛选(HTS)试验来鉴定GLP-1模拟肽。该试验基于GLP-1受体(GLP-1R)基因进行功能检测。通过脂质转染将大鼠GLP-1R cDNA转染至CHO/增强型绿色荧光蛋白(EGFP)细胞中。所得稳定的重组细胞系功能性表达GLP-1R和一个cAMP反应性EGFP报告基因,用于监测受体激活情况,并用于筛选PhD十二肽库。经过四轮筛选后,基于功能评估选择了10个阳性克隆并进行测序。获得了三个序列,分别对应GLP-1的三个不同结构域(第1组:22-34;第2组:18-29;第3组:6-17)。第3组肽具有最高的生物活性,合成后命名为KS-12。重要的是,KS-12在体外可激活GLP-1R,给中国昆明小鼠给药时可剂量依赖性降低血糖水平。虽然KS-12不如GLP-1有效,但在体外和体内对DPP-IV均具有显著抗性。因此,本研究提供了一种利用功能报告基因HTS试验从PhD肽库中筛选GLP-1的DPP-IV抗性激动剂肽的新方法。